Skip to main content

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic drugs for treating serious autoimmune and kidney diseases. The company's flagship commercial product is Lupkynis (voclosporin), an immunosuppressive agent approved for the treatment of adult patients with active lupus nephritis. Its core operations encompass commercial biopharmaceutical distribution, clinical-stage drug development, and immunological research. Revenue is derived primarily from the global commercial sales of Lupkynis to healthcare providers and specialty pharmacies. Aurinia Pharmaceuticals holds a specialized position in nephrology therapeutics and autoimmune disease management. The company is headquartered in Victoria, British Columbia, Canada, with operational headquarters in Edmonton, and its common shares trade on the Nasdaq Global Select Market and the Toronto Stock Exchange.

7 of the funds FundTelligence covers report a position in Aurinia Pharmaceuticals.

Legal name
Aurinia Pharmaceuticals Inc
Sector
Health Care
Country
Canada
Funds holding it
7

Funds holding Aurinia Pharmaceuticals

Loading...